Brian Haddigan: Beyond Stent Design – The Importance of Blood Compatibility
Brian Haddigan, Chief Executive Officer and Co Founder at Smart Reactors, shared a post on LinkedIn:
“What if the next breakthrough in venous stents isn’t the design, but the surface?
FDA post-market surveillance continues to receive reports of thrombosis, occlusion and restenosis associated with venous stents.
While these reports don’t measure complication rates, they reinforce that blood compatibility remains an important challenge.
Smart Reactors we’ve developed Camouflage, an ultra-thin, non-pharmacological hemocompatible coating designed to create a more blood-friendly surface, reducing platelet and fibrin adhesion while supporting natural healing.
The future of vascular implants includes solid engineering and smarter surfaces.
Could your next-generation device benefit from Camouflage?
Lets connect and find out..”
Stay updated with Hemostasis Today.
-
Oct 2, 2026, 14:30Sadashiva Pai: The Molecular Gateway for Sphingosine-1-Phosphate Release
-
Oct 2, 2026, 14:17Aditya Rawat: Clopidogrel, CYP2C19 and the Role of Pharmacogenetics
-
Oct 2, 2026, 14:12Monitoring Iron Deficiency in Glanzmann Thrombasthenia – Glanzmann’s Research Foundation
-
Oct 2, 2026, 14:06Giang Tran: Residual Internal Carotid Artery Aneurysm After Flow-Diverter Stenting
-
Oct 2, 2026, 14:05Shadiah Nassanga: The Economic Impact of Sickle Cell Disease
-
Oct 2, 2026, 13:56Mapping the Care Gaps for Hemophilia and Sickle Cell Disease in Ghana – Novo Nordisk Haemophilia and Haemoglobinopathies Foundation
-
Oct 2, 2026, 13:50Arnav Garcha: New Insights Into Platelet Transport in Arterial Flow
-
Oct 2, 2026, 13:49Alessandro Lucchesi: RiseMPN 2026 – Shaping the Future of MPN Treatment
-
Oct 2, 2026, 13:43Ronald Mahomane: Bangladesh Moves Toward Sustainable Hemophilia Treatment Access